Introducing BTK Inhibition in Primary CNS Lymphoma

Dr. Lakshmi Nayak introduces the discussion on primary CNS lymphoma (PCNSL) and the evolving role of Bruton tyrosine kinase (BTK) inhibition in this rare and aggressive B-cell malignancy. She is joined by Dr. Christian Grommes, Dr. Motoo Nagane, and Dr. Chieh-Lung Cheng, who bring clinical perspectives from the United States, Japan, and Taiwan. The conversation will examine the biology of PCNSL, the rationale for targeting BTK signaling, and the treatment challenges that remain in the relapsed or refractory setting, where therapeutic options are limited. Dr. Nayak also outlines the program's focus on clinical trial experience and real-world use of BTK inhibitors, including experience with tirabrutinib in Japan and Taiwan, where it is approved for relapsed or refractory PCNSL. The faculty will place these international experiences within the broader BTK inhibitor landscape. The discussion is educational in nature, with Dr. Nayak emphasizing that tirabrutinib remains investigational in the United States and has not been approved by the FDA.